Sep-Pak eluate (% ACN/TFA) . | S1-like immunoreactivity (pmol) . | . | S2-like immunoreactivity (pmol) . | . | . | |||
---|---|---|---|---|---|---|---|---|
. | BLII . | SLII . | BGI . | CLII . | TRII . | |||
20 | 9 | 1 | 54 | 65 | 55 | |||
40 | 35 | 32 | 903 | 1293 | 443 | |||
60 | 12 | 1 | 799 | 364 | 544 | |||
80 | 2 | 0 | 48 | 6 | 90 |
Sep-Pak eluate (% ACN/TFA) . | S1-like immunoreactivity (pmol) . | . | S2-like immunoreactivity (pmol) . | . | . | |||
---|---|---|---|---|---|---|---|---|
. | BLII . | SLII . | BGI . | CLII . | TRII . | |||
20 | 9 | 1 | 54 | 65 | 55 | |||
40 | 35 | 32 | 903 | 1293 | 443 | |||
60 | 12 | 1 | 799 | 364 | 544 | |||
80 | 2 | 0 | 48 | 6 | 90 |
ACN, acetonitrile; TFA, trifluoroacetic acid.
Radioimmunoassay with two S1 antisera (BLII, SLII) and three S2 antisera(BGI, CLII, TRII) reveals the majority of the SALMFamide-like immunoreactivity in the 40% and 60% ACN/TFA eluates. Note that the Echinus material is much more immunoreactive with the S2 antisera than the S1 antisera.